Software M&A advisory for Healthcare

Software M&A advisory healthcare buyers rely on has to account for a system estate that is older, more integrated, and more regulated than most. A hospital group, a payer, or a health technology company runs clinical systems, electronic health records, billing platforms, and a back office of enterprise software, all stitched together by interface engines that move data constantly. That integration is what makes care work, and it is also what creates licensing exposure no one has measured. We map and quantify that exposure before a deal, and reconcile it after close, independently and paid only by the acquirer.

Why software M&A advisory for healthcare is different

Healthcare estates carry risk in a particular shape. Systems are long lived, so entitlement records drift away from deployment over a decade or more. They are tightly integrated, so data flows between clinical, billing, and reporting systems in ways that create indirect access exposure on the underlying platforms. And they are rarely reconciled, because clinical continuity always takes priority over license housekeeping. The result is a target whose true licensing position is unknown to the seller and invisible in the accounts. The major audit risks come from Oracle, SAP, Microsoft and IBM, and increasingly Broadcom following VMware, each of which has the contractual right to audit and the commercial reason to do so once ownership changes.

The exposures we map for healthcare buyers

Our software due diligence for a healthcare target focuses on four areas. First, indirect access: the interface engines and downstream applications that read data from a licensed core system without each user holding a license, a pattern that can create large unbudgeted exposure on SAP or Oracle. Second, clinical and electronic health record licensing, where metrics are complex and vendor specific. Third, the enterprise back office, where named user and processor metrics on Oracle, SAP, Microsoft and IBM rarely match the deployed reality. Fourth, the duplicate departmental tools that two merged providers or payers almost always run side by side. Each exposure is tested against the deal structure, because assignment and change of control terms decide which agreements need consent.

From diligence to post close value

After close, a healthcare integration is constrained by the need to protect care, so licensing work has to be careful and sequenced. Connecting two estates can extend indirect access and push user counts past entitlement, and the systems involved cannot simply be switched off to fix a license gap. Our post close license reconciliation builds the true position of the combined entity and resolves breaches in a controlled way, before a publisher audit forces the issue. Public disputes show the scale possible, with SAP reported to have pursued AB InBev for around 600 million dollars and Diageo for around 60 million over disputed and inherited licensing, as reported by Reuters and accurate as of June 2026. Where the deal is a buy and build, integration and consolidation standardises the approach so every site is mapped the same way.

Common findings in healthcare deals

Healthcare targets surface a consistent set of findings that the seller almost never quantifies. Indirect access is the largest. Interface engines move patient and billing data between clinical systems, portals, and reporting tools, and each of those downstream reads can require a license on the core platform it touches. In a busy provider estate this exposure compounds quietly for years. Alongside it sit entitlement gaps on the enterprise back office, where Oracle and SAP user and processor counts were set during an implementation a decade ago and have drifted ever since. Microsoft and infrastructure licensing is usually under counted because virtual environments grew faster than the agreements that govern them. And almost every merged provider or payer runs duplicate departmental systems, a second scheduling tool here, a second analytics platform there, because consolidating them was never urgent enough to interrupt care.

The pattern that ties these together is that clinical priority always outranks license housekeeping, and rightly so. But that priority is exactly why the exposure stays hidden until a publisher audit makes it visible. A buyer who maps it before signing can price it, build it into the warranties, or plan a controlled remediation. A buyer who inherits it blind faces a demand on a system that cannot be switched off, with little room to negotiate. The value of an independent review is turning that latent, unquantified risk into a number the deal team can use while there is still time to act on it.

How we work alongside the deal team

We take the software estate while the rest of the deal process runs as normal. The corporate development or sponsor team leads the transaction, the financial and clinical advisors cover their areas, and your counsel and compliance team own the legal and regulatory interpretation. We focus on the licensing and audit exposure, reading the data room for the master agreements that matter, tracing the integrations that drive indirect access, and reconciling entitlement against deployment on the systems most likely to breach. The result is a quantified position, a sequenced remediation plan that protects clinical continuity, and a view of the consolidation savings available once the estates are combined. We bring no publisher relationship to the table, so the answer we give serves the buyer and no one else.

Independent, buyer side, paid by you

We resell no software and hold no publisher or reseller affiliation. For a healthcare buyer, that independence matters because the systems are mission critical and the publishers know it, which gives them leverage a conflicted advisor will not push back on. We are paid only by the acquirer, and our goal is the cleanest, lowest cost, lowest risk position for the deal. This is commercial and licensing advisory, not legal advice, and we work alongside your own counsel and compliance team. Where consent is needed, we support it through change of control and assignment review.